Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Keytruda = $265,000 (17 doses per year)

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Apr 13, 2023 8:54pm

123 Views

Post# 35394341

RE:RE:RE:Keytruda = $265,000 (17 doses per year)

CancerSlayer wrote:

DJDawg wrote: Hi

I may be wrong but there is also the maint protocol for the last one so more likely to be 16-20 doses total.

Nadofaragene = $313,000 (4 doses for first year; up to 16 doses over 4 years)
Oportuzumab = $310,000 (36 doses in first year)
Keytruda = $265,000 (17 doses per year)
Gemcitabine + Docetaxel = $172,000 (6 doses total) - then monthly x 10 to 24 months depending on response.

Thanks Dawg...no matter how you look at it, the current & future competition will entail a lot of doses at significant costs, both fiscal & treatment-burden wise. Cost & dosing factors will continue to play a big role in terms of ultimate commercial viability. Considering the above factors would have a net negative impact on viability, your efficacy rates better reign supreme. This certainly hasn't been the case thus far...

Current FDA approved treatments (12 month CR):

1). Valrubicin = 18%
2). Nadofaragene = 24%
3). Keytruda = 19%

Note:

1). Oportuzumab was rejected for approval by FDA (12 month CR = 18%)

2). Gemcitabine plus Docetaxel are being used off-label. This serial treatment is currently not FDA approved, however, it is frequently being used for BCG-naive high-risk NMIBC (primarily due to the BCG shortage & promising retrospective data) & also as salvage therapy for some BCG-unresponsive patients.

As you know, there is a blatantly huge opportunity staring at our faces...personally, hoping for a partnership with a well-financed, but more niche/medium-sized, pharma/tech company. Want to drive up value as much as possible before any Big Pharma tries to sink its claws into us ; ).